Company Overview of Editas Medicine, Inc.
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome ed...
11 Hurley Street
Cambridge, MA 02142
Founded in 2013
Key Executives for Editas Medicine, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $450.0K
Chief Financial Officer
Total Annual Compensation: $157.5K
Chief Medical Officer
Total Annual Compensation: $100.0K
Chief Scientific Officer
Total Annual Compensation: $136.5K
Compensation as of Fiscal Year 2016.
Editas Medicine, Inc. Key Developments
Editas Medicine, Inc. Announces Results from Experiments to Demonstrate Expanded CRISPR Genome Editing Strategies in Hematopoietic Stem Cells for the Treatment of Hematologic Diseases
Dec 11 17
Editas Medicine, Inc. announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of hematologic diseases such as sickle cell disease and beta-thalassemia. In these proof of concept experiments, the company demonstrated CRISPR/Cas9 homology directed repair (HDR) and CRISPR/Cpf1-directed editing in human CD34+ cells. The company reported these data in a poster presentation at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta. In experiments, CRISPR/Cas9 caused efficient and reproducible HDR in CD34+ cells with minimal impact on cell viability. In separate studies, CRISPR/Cpf1 efficiently edited at multiple sites, including targets associated with hereditary persistence of fetal hemoglobin (HPFH). These results confirm that Cpf1-directed editing expands the number of genomic sites accessible to develop genome editing medicines.
Editas Medicine Eyes Acquisitions
Dec 5 17
Editas Medicine, Inc. (NasdaqGS:EDIT) is looking for acquisitions. Editas Medicine raised $50 million in public offering of shares and intends to use the net proceeds for general corporate purposes may include, without limitation, research and development expenditures, the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.
Editas Medicine, Inc. Presents at 13th Annual Personalized Medicine Conference, Nov-15-2017 01:00 PM
Nov 11 17
Editas Medicine, Inc. Presents at 13th Annual Personalized Medicine Conference, Nov-15-2017 01:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Katrine S. Bosley, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|